Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol
Vaidyanathan Ganapathy,1 Michael D Stensland2 1Sunovion Pharmaceuticals Inc., Marlborough, MA, 2Agile Outcomes Research, Inc., Rochester, MN, USA Objective: Arformoterol is the (R,R)-enantiomer of formoterol. Preclinical studies suggest that it is a stronger bronchodilator than the racemic (R,R/S,...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2017-06-01
|
| Series: | International Journal of COPD |
| Subjects: | |
| Online Access: | https://www.dovepress.com/health-resource-utilization-for-inpatients-with-copd-treated-with-nebu-peer-reviewed-article-COPD |